Check Credit Score
Check Credit Score
HomeNewsIndia

COVID-19 treatment | Contradictory guidelines issued on use of plasma therapy

The therapy involves transfusing plasma from a patient who has recovered from COVID-19, into a sick patient so that the latter may benefit from the possible antibodies generated in the blood of the patient who has already recovered.

July 01, 2020 / 09:29 AM IST

New orders issued by different arms of the Union Health Ministry on plasma therapy for treatment of COVID-19 patients are sending contradictory signals.

According to a report in The Hindu BusinessLine, the latest guidelines issued by the National Blood Transfusion Council (NBTC) states that the use of convalescent plasma for routine treatment of COVID-19 patients is currently not recommended.

This is in contradiction to the Union Health Ministry’s clinical management protocol, issued on June 27, which says that ‘off-label’ use of convalescent plasma may be considered in patients with moderate disease who are not improving despite use of steroids.

‘Off-label’ refers to use of an unapproved drug or treatment of a disease or a medical condition.

The protocol suggests that these patients be transfused with a single dose of 200 ml slowly over not less than two hours.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

The therapy involves transfusing plasma from patients who have recovered from COVID-19 into active cases so that the latter may benefit from the possible antibodies generated in the blood of those who have already recovered. In theory, this should help patents recover after transfusion.

The Indian Council for Medical Research (ICMR)’s study on plasma therapy is still going on.

On June 29, Maharashtra government announced ‘Project Platina’, a plasma therapy trial on COVID-19 patients. The trial is being pegged as the world's largest.

As many as 21 centres have been picked for the trial, including 17 medical colleges under the Medical Education & Drugs Department (MEDD), and four medical colleges in Mumbai under the municipal corporation.

On the same day, Delhi Chief Minister Arvind Kejriwal announced setting up a 'plasma bank' in the national capital to help save seriously-ill COVID-19 patients.

Kejriwal also urged those who had been cured of COVID-19 to donate their plasma.

Click here for Moneycontrol’s full coverage of the novel coronavirus pandemic

Moneycontrol News
first published: Jul 1, 2020 09:18 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347